118 related articles for article (PubMed ID: 15934897)
21. Duloxetine for the treatment of major depressive disorder.
Nemeroff CB; Schatzberg AF; Goldstein DJ; Detke MJ; Mallinckrodt C; Lu Y; Tran PV
Psychopharmacol Bull; 2002; 36(4):106-32. PubMed ID: 12858150
[TBL] [Abstract][Full Text] [Related]
22. The dual transporter inhibitor duloxetine: a review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression.
Bymaster FP; Lee TC; Knadler MP; Detke MJ; Iyengar S
Curr Pharm Des; 2005; 11(12):1475-93. PubMed ID: 15892657
[TBL] [Abstract][Full Text] [Related]
23. A randomized placebo-controlled trial of duloxetine in patients with major depressive disorder and associated painful physical symptoms.
Gaynor PJ; Gopal M; Zheng W; Martinez JM; Robinson MJ; Marangell LB
Curr Med Res Opin; 2011 Oct; 27(10):1849-58. PubMed ID: 21838411
[TBL] [Abstract][Full Text] [Related]
24. Duloxetine: a review of its use in the treatment of major depressive disorder.
Frampton JE; Plosker GL
CNS Drugs; 2007; 21(7):581-609. PubMed ID: 17579500
[TBL] [Abstract][Full Text] [Related]
25. Duloxetine in the treatment of elderly people with major depressive disorder.
Del Casale A; Girardi P; Brugnoli R; Sani G; Di Pietro S; Brugnoli C; Caccia F; Angeletti G; Serata D; Rapinesi C; Tatarelli R; Kotzalidis GD
Riv Psichiatr; 2012; 47(6):479-88. PubMed ID: 23160108
[TBL] [Abstract][Full Text] [Related]
26. Duloxetine treatment of pediatric chronic pain and co-morbid major depressive disorder.
Meighen KG
J Child Adolesc Psychopharmacol; 2007 Feb; 17(1):121-7. PubMed ID: 17343560
[TBL] [Abstract][Full Text] [Related]
27. Incidence and duration of antidepressant-induced nausea: duloxetine compared with paroxetine and fluoxetine.
Greist J; McNamara RK; Mallinckrodt CH; Rayamajhi JN; Raskin J
Clin Ther; 2004 Sep; 26(9):1446-55. PubMed ID: 15531007
[TBL] [Abstract][Full Text] [Related]
28. Relationship between major depressive disorder and associated painful physical symptoms: analysis of data from two pooled placebo-controlled, randomized studies of duloxetine.
Robinson MJ; Sheehan D; Gaynor PJ; Marangell LB; Tanaka Y; Lipsius S; Ohara F; Namiki C
Int Clin Psychopharmacol; 2013 Nov; 28(6):330-8. PubMed ID: 23873291
[TBL] [Abstract][Full Text] [Related]
29. Is duloxetine's effect on painful physical symptoms in depression an indirect result of improvement of depressive symptoms? Pooled analyses of three randomized controlled trials.
Harada E; Tokuoka H; Fujikoshi S; Funai J; Wohlreich MM; Ossipov MH; Iwata N
Pain; 2016 Mar; 157(3):577-584. PubMed ID: 26882344
[TBL] [Abstract][Full Text] [Related]
30. The safety and tolerability of duloxetine in depressed elderly patients with and without medical comorbidity.
Wise TN; Wiltse CG; Iosifescu DV; Sheridan M; Xu JY; Raskin J
Int J Clin Pract; 2007 Aug; 61(8):1283-93. PubMed ID: 17590215
[TBL] [Abstract][Full Text] [Related]
31. False conclusions regarding duloxetine's purported efficacy in pain among depressed patients.
Spielmans GI
Psychiatr Danub; 2010 Dec; 22(4):550; author reply 551. PubMed ID: 21169898
[No Abstract] [Full Text] [Related]
32. A word of caution about the implied role for duloxetine in pain management.
Leo RJ
J Clin Psychiatry; 2003 Oct; 64(10):1270. PubMed ID: 14658982
[No Abstract] [Full Text] [Related]
33. Duloxetine versus placebo in the treatment of major depressive disorder and associated painful physical symptoms: a replication study.
Gaynor PJ; Gopal M; Zheng W; Martinez JM; Robinson MJ; Hann D; Marangell LB
Curr Med Res Opin; 2011 Oct; 27(10):1859-67. PubMed ID: 21838410
[TBL] [Abstract][Full Text] [Related]
34. The effect of pain on outcomes in a trial of duloxetine treatment of major depressive disorder.
Arnold LM; Meyers AL; Sunderajan P; Montano CB; Kass E; Trivedi M; Wohlreich MM
Ann Clin Psychiatry; 2008; 20(4):187-93. PubMed ID: 19034749
[TBL] [Abstract][Full Text] [Related]
35. Measurement of pain and medication effect in a study of duloxetine.
Griffith JM; Hasley JP; Severn DG
J Clin Psychiatry; 2008 Jun; 69(6):1022. PubMed ID: 18684005
[No Abstract] [Full Text] [Related]
36. Preclinical discovery of duloxetine for the treatment of depression.
Torres-Sanchez S; Perez-Caballero L; Mico JA; Elorza J; Berrocoso E
Expert Opin Drug Discov; 2012 Aug; 7(8):745-55. PubMed ID: 22680253
[TBL] [Abstract][Full Text] [Related]
37. Time to response for duloxetine 60 mg once daily versus placebo in elderly patients with major depressive disorder.
Raskin J; Xu JY; Kajdasz DK
Int Psychogeriatr; 2008 Apr; 20(2):309-27. PubMed ID: 17588276
[TBL] [Abstract][Full Text] [Related]
38. Duloxetine compared with fluoxetine and venlafaxine: use of meta-regression analysis for indirect comparisons.
Eckert L; Lançon C
BMC Psychiatry; 2006 Jul; 6():30. PubMed ID: 16867188
[TBL] [Abstract][Full Text] [Related]
39. Trajectory analysis of healthcare costs for patients with major depressive disorder treated with high doses of duloxetine.
Cui Z; Faries DE; Zhao Y; Novick D; Liu X
J Med Econ; 2011; 14(5):662-72. PubMed ID: 21892857
[TBL] [Abstract][Full Text] [Related]
40. Time course of depression-symptom improvement during treatment with duloxetine.
Hirschfeld RM; Mallinckrodt C; Lee TC; Detke MJ
Depress Anxiety; 2005; 21(4):170-7. PubMed ID: 16035056
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
